In utero engraftment of fully H-2-incompatible versus congenic adult bone marrow transferred into nonanemic or anemic murine fetal recipients.
In utero engraftment of fully H-2-incompatible versus congenic adult bone marrow transferred into nonanemic or anemic murine fetal recipients.
复制标题
将完全 H-2 不相容的与同源的成年骨髓在子宫内移植到非贫血或贫血的小鼠胎儿受体中。
DOI：
10.1097/00007890-199309000-00039
复制
发表时间：
1993
期刊：
影响因子：
6.2
通讯作者：
Blazar,BR
中科院分区：
文献类型：
--
作者：
Howson-Jan,K;Matloub,YH;Vallera,DA;Blazar,BR
我们建立了小鼠子宫内骨髓移植模型系统，并研究了供体品系差异、细胞剂量和注射次数对小鼠胎儿存活率和植入率的影响。在一系列实验中，1221 个非贫血 C57BL/6 胎儿在妊娠第 11 天经胎盘注射来自 C57BL/6-CAST（同源）、BALB/c 和 DBA/1（同种异体）品系的 10 个非 T 耗尽的成年骨髓细胞 (BMC)，无需接受受体调节。 475 名可评估的第 5 天新生儿的总体胎儿存活率为 45%，植入率为 4%。移植新生儿最初的供体外周血细胞移植率高达 75-100%，尤其是 DBA/1 BMC。令人惊讶的是，与同源供体（0.7%）相比，同种异体供体（5.2%）的植入发生率显着（P<0.05）较高。然而，所有组中的移植都是短暂的，因为所研究的移植受体在出生后6周时具有不可检测的供体细胞水平。相比之下，将同种骨髓移植到贫血、干细胞缺陷的 W"/"W" 受者中会导致较高的移植发生率 (4O%)，并持续 6 周，移植水平随着时间的推移而增加。进行了其他研究，试图进一步提高移植的发生率和持久性。细胞剂量加倍或注射次数加倍都没有改善重新移植的移植率。
We have established a murine in utero bone marrow transplantation model system and have investigated the effects of donor strain differences, cell dose, and the number of injections on murine fetal survival and engraftment rates. In a series of experiments, 1221 nonanemic C57BL/6 fetuses were injected transplacentally on day 11 of gestation with 10 non-T-depleted adult bone marrow cells (BMC) from C57BL/6-CAST (congenic), BALB/c and DBA/1 (allogeneic) strains without recipient conditioning. Overall fetal survival was 45%, with a 4% engraftment rate in 475 evaluable day 5 newborns. Engrafted newborns initially had up to 75–100% donor peripheral blood cell engraftment, particularly with DBA/1 BMC. Surprisingly, a significantly (P< 0.05) higher incidence of engraftment was observed using allogeneic (5.2%) as compared with congenic donors (0.7%). However, engraftment in all groups was transient since engrafted recipients studied= 6 weeks post-natally had nondetectable levels of donor cells. In contrast, engraftment of congeneic marrow into anemic, stem cell–defective W"/" W" recipients lead to a higher incidence (4O%) of engraftment that persisted for= 6 weeks, increasing in the level of engraftment over time. Additional studies were performed in an attempt to further increase the incidence and permanence of engraftment. Neither doubling the cell dose nor doubling the number of injections improved engraftment rates in re-